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A B S T R A C T
The hypomethylating agents (HMAs), decitabine and azacitidine, are valuable treatment options in acute
myeloid leukemia patients who are not eligible for intensive chemotherapy. Both agents are generally well
tolerated, and complications most commonly relate to myelosuppression. Antibiotic / antifungal use, regular
monitoring, and proactive patient education are important to minimize these events, and reduce the need for
dose delay. Responses to HMAs are often not evident for up to 6 cycles, and there is currently no validated
clinical marker for predicting response. Hence, treatment should be continued for at least 4–6 cycles to ensure
that patients have sufficient opportunity to respond. Delivery of insufficient numbers of cycles is a key reason for
HMA failure, and premature discontinuation must be avoided. Genetic factors offer potential for better pre-
dicting responders to HMAs in future, but require further study.
1. Introduction
Hypomethylating agents (HMAs) are an important treatment option
in patients with acute myeloid leukemia (AML) who are not considered
to be candidates for intensive chemotherapy (Döhner et al., 2017). Two
HMAs have been licensed in Europe for the treatment of these patients:
decitabine and azacitidine (Dacogen SmPC; Vidaza SmPC). Both are
indicated for the treatment of adult patients with newly diagnosed AML
who are not candidates for standard induction chemotherapy (Dacogen
SmPC; Vidaza SmPC). Both work by DNA methyltransferase-1 deple-
tion, DNA hypomethylation, and chromatin reorganization (Hollenbach
et al., 2010; Kim et al., 2015). Azacitidine has effects on both RNA and
DNA, whereas decitabine has no direct effects on RNA (Kim et al.,
2015)
The use of HMAs in AML follows the experience with these drugs in
myelodysplastic syndrome (MDS), and there is significant overlap in the
recommendations for practical use. However, it is important to re-
member that AML patients have distinctive clinical characteristics.
Decitabine and azacitidine have proven efficacy and safety in Phase
3 trials in AML. The DACO-016 study randomized 485 patients aged ≥
65 years (who were not considered to be candidates for standard in-
duction chemotherapy) to either decitabine 20mg/m2/day as a 1 -h
intravenous (IV) infusion for 5 consecutive days every 4 weeks or to
treatment choice (TC; best supportive care [BSC] or cytarabine 20mg/
m2/day as a subcutaneous [SC] injection for 10 consecutive days every
4 weeks) (Kantarjian et al., 2012). The primary analysis showed a non-
significant increase in median overall survival (OS) with decitabine
versus TC (7.7 vs 5.0 months, respectively; hazard ratio [HR]: 0.85;
95% confidence interval [CI]: 0.69–1.04; p= 0.108); this difference
became statistically significant in a pre-planned analysis in which pa-
tients who received subsequent disease-modifying therapy were cen-
sored (median OS: 8.5 vs 5.3 months; HR: 0.80; 95% CI: 0.64–0.99;
p=0.044), and in an unplanned mature analysis (median OS: 7.7 vs
5.0 months; HR: 0.82; 95% CI: 0.68–0.99; p=0.037) (Kantarjian et al.,
2012). Meanwhile, the AZA-AML-001 trial randomized 488 patients
aged ≥ 65 years to azacitidine 75mg/m2/day SC for 7 consecutive days
every 4 weeks or conventional care (BSC, cytarabine 20mg twice daily
for 10 consecutive days every 4 weeks, or induction chemotherapy with
cytarabine and daunorubicin/idarubicin) (Dombret et al., 2015). There
was a non-significant improvement in median OS with azacitidine
versus conventional care (10.4 vs 6.5 months, respectively; HR: 0.85;
95% CI: 0.69–1.03; p=0.101), which reached statistical significance
when censoring patients who received AML treatment after dis-
continuing study drug (median OS: 12.1 vs 6.9 months; HR: 0.76; 95%
CI: 0.60–0.96; p= 0.019) (Dombret et al., 2015).
No randomized trial has ever directly compared decitabine and
azacitidine in AML. Furthermore, indirect comparisons of the Phase 3
trials are complicated by important differences in the inclusion criteria,
https://doi.org/10.1016/j.critrevonc.2019.05.013
Received 23 October 2018; Received in revised form 13 May 2019; Accepted 14 May 2019
⁎ Corresponding author.
E-mail address: g.ossenkoppele@vumc.nl (G.J. Ossenkoppele).
Critical Reviews in Oncology / Hematology 140 (2019) 1–7
1040-8428/ © 2019 Elsevier B.V. All rights reserved.
T
comparator arm, and treatment duration (Kantarjian et al., 2012;
Dombret et al., 2015; Schuh et al., 2017). A recent analysis of outcomes
from>2000 patients receiving frontline AML treatment with decita-
bine or azacitidine in a US database found that median OS was similar
with the two compounds (Mehra et al., 2017). Similarly, retrospective
analyses in patients with MDS have typically found no difference be-
tween decitabine and azacitidine in OS or response rates (Lee et al.,
2013a; Zeidan et al., 2016), although a Korean study observed that each
HMA may be superior to the other in particular patient subgroups (Lee
et al., 2013b). Current AML guidelines from the European LeukemiaNet
(ELN) give both drugs equal weighting as options for patients who are
not candidates for intensive chemotherapy (Döhner et al., 2017).
There is currently no widely adopted, standardized definition of
‘suitability’ or ‘fitness’ for intensive chemotherapy. However, attempts
have been made to establish such a classification. For example, the
Italian hematology and transplant societies developed a definition
based on factors such as age, comorbidities and performance status
(Ferrara et al., 2013). Furthermore, the use of extended geriatric as-
sessments focusing on cognitive and physical function may improve the
prediction of survival in older patients being considered for induction
chemotherapy (Klepin et al., 2013; Sherman et al., 2013; Klepin, 2014).
Given that it is often their only chance for cure, all patients should be
assessed for intensive treatment but, in practice, many patients are
considered not to be fit enough to receive it.
2. Administration of HMAs
The recommended dose and administration of both approved HMAs
is as per the Phase 3 registration trials. Decitabine should be given at
20mg/m2 of body surface area, IV, daily on the first 5 days of each 4-
week cycle (Dacogen SmPC). A central venous catheter is usually not
required. Decitabine infusion should last 1 h. For azacitidine, the re-
commended schedule is 75mg/m2 of body surface area, SC, given daily
on the first 7 days of each 4-week cycle (Vidaza SmPC). For both drugs,
a protocol of administration should be developed by individual centers,
providing also hydration and anti-emetics, if required. In the majority
of patients, HMAs can be given on an outpatient basis; home adminis-
tration could be a possibility with azacitidine although this is currently
not allowed in many countries. Subcutaneous injections can be given in
the abdomen, legs or arms in a clockwise fashion, without exceeding
1mL infusion per injection site and without priming the syringe.
Either HMA should be continued for a minimum of 4–6 cycles unless
clear progression or intolerance are documented (Dacogen SmPC;
Vidaza SmPC).
Other HMA dosing regimens have been assessed. In fact, decitabine
was first studied with a different schedule and dose – 15mg/m2 deci-
tabine given three times daily on 3 consecutive days (total dose
135mg/m2) every 6 weeks – based on its pharmacokinetics and sup-
posed hypomethylating activity, and the safety and efficacy of this re-
gimen has been demonstrated (Lübbert et al., 2012). Furthermore, a
decitabine schedule of 20mg/m2/day given for 10 days of each 28-day
cycle has shown promising results across several studies (Blum et al.,
2010; Ritchie et al., 2013; Bhatnagar et al., 2014; Welch et al., 2016),
and a meta-analysis of non-comparative studies suggested that response
rates were significantly higher than with the conventional 5-day re-
gimen (He et al., 2017a). However, a recent, randomized Phase 2 study
comparing the efficacy of the 5- and 10-day regimens in adults aged ≥
60 years with newly diagnosed AML found no significant difference in
response rate or survival (Short et al., 2017). An ongoing Phase 3 study
run by the European Organisation for Research and Treatment of
Cancer (EORTC) is comparing 10-day decitabine with standard ‘7+ 3’
combination chemotherapy followed by allografting in patients aged ≥
60 years with newly diagnosed AML (NCT02172872).
With azacitidine, practical considerations based around avoiding
weekend administration have led to the use of alternative regimens,
such as 5 days of azacitidine 75mg/m2/day, or 5 days followed by a
weekend break followed by an additional 2 days of azacitidine 75mg/
m2/day. There has been no signal to intimate that this results in inferior
outcomes, but no studies have yet made a direct comparison and these
regimens have not been approved. A systematic review of studies
conducted in patients with AML, MDS or chronic myelomonocytic
leukemia suggested similar response rates across dosing schedules
(Shapiro et al., 2015).
A recent Phase 2 study in 113 patients with lower-risk MDS or MDS/
myeloproliferative neoplasm demonstrated the efficacy and safety of a
shortened 3-day schedule of decitabine 20mg/m2/day or azacitidine
75mg/m2/day (Jabbour et al., 2017). Overall response rates with low-
dose decitabine or azacitidine were 70% and 49%, respectively
(p= 0.03), and 6-week mortality was 0%. However, neither 3-day
schedule has been tested in AML.
For the moment, in the context of normal clinical practice, physi-
cians should adhere to conventional HMA regimens as per their ap-
proved indications, based on their proven response rates and effects on
survival (Dacogen SmPC; Vidaza SmPC).
3. Managing adverse events
Both HMAs were generally well tolerated in Phase 3 trials in AML,
and rates of discontinuation due to treatment-related adverse events
(AEs) were low (< 10%) given the context of higher-risk older patients
(Kantarjian et al., 2012; Dombret et al., 2015).
3.1. Hematologic AEs
Although decitabine and azacitidine are less cytotoxic than in-
tensive chemotherapy and are very rarely associated with AEs like
mucositis or hepatic damage, specific considerations remain when
managing this population, who are frequently elderly and/or comorbid.
Indeed, AML outpatients always require particular care and attention,
especially during the intervals between cycles when they are managed
at home. AEs with azacitidine or decitabine are most commonly related
to myelosuppression or the complications of myelosuppression (e.g.
infection or bleeding) (Kantarjian et al., 2012; Dombret et al., 2015).
Prophylactic wide-spectrum antibiotic use is recommended in patients
receiving HMA therapy, and prophylactic antifungal use should also be
considered if the neutrophil count falls below 500/μL.
Growth factor support has no proven benefit in AML, but can be
employed in the intervals between cycles in case of infection and per-
sistent severe neutropenia. However, these compounds are not re-
commended during the days in which HMAs are administered, owing to
the S-phase specificity of the drugs and the growth factor-induced sti-
mulation of hematopoietic cell proliferation. Concurrent administration
of myeloid growth factors and an HMA may result in higher uptake of
the drug and an increase in cytotoxicity, although this has not been
specifically demonstrated in clinical trials.
Complete blood and platelet counts should be taken before each
treatment cycle, and on a weekly basis during the treatment itself
(particularly during early cycles) (Dacogen SmPC; Vidaza SmPC). Pa-
tients should be monitored for myelosuppression, as well as signs of
infection or bleeding, and treated promptly. Patients with AML re-
ceiving HMA treatment normally need not be hospitalized, given the
typically long duration of therapy (at least 6 cycles). Hence, they must
be followed with particular attention, with at least weekly counts, and
instructed to contact the treating physician immediately if they ex-
perience a fever or any persistent symptom like dyspnea, cough or
bleeding. Transfusions should be performed as required and possibly
programmed, particularly during early cycles in cases of symptomatic
anemia or thrombocytopenia.
If a patient experiences myelosuppression-associated complications,
the best strategy is not to lower the dose, but to delay the next treat-
ment cycle at the discretion of the treating physician. In clinical trials,
around a third of patients required at least one such delay (Dacogen
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SmPC), although the proportion is lower in our practice, probably
through more optimal application of antibiotic and antifungal agents.
The decitabine Summary of Product Characteristics (SmPC) lists the
following as potential situations in which dose delay might be con-
sidered (Dacogen SmPC), and the same broadly applies with azaciti-
dine:
• Febrile neutropenia (temperature ≥ 38.5 °C and absolute neutrophil
count< 1000/μL);
• Active viral, bacterial or fungal infection (requiring IV anti-in-
fectives or extensive supportive care);
• Uncontrollable hemorrhage (gastrointestinal, genitourinary, pul-
monary, or any central nervous system hemorrhage).
Treatment should be resumed as soon as possible once the patient’s
condition has been stabilized or improved. Cycles should not be delayed
longer than necessary, owing to the presumed mechanism of action of
hypomethylating agents: if the interval is excessive, DNA hy-
permethylation may be restored and the efficacy of treatment dimin-
ished.
In decitabine-treated patients, dose reduction is not recommended
as an alternative to dose delay in cases of myelosuppression (Dacogen
SmPC). The same approach is preferred with azacitidine, although the
Summary of Product Characteristics (SmPC) recommends a dose re-
duction of 50% if a recovery in absolute neutrophil / platelet counts is
not achieved within 14 days (Vidaza SmPC). It should be stressed that,
in practice, this is rarely applicable, because neutrophil counts are often
very low at the start of therapy.
If hematologic values do not return to pre-treatment levels or im-
prove within 4 cycles, it may be necessary to re-evaluate a marrow
aspiration to assess disease progression, and terminate HMA therapy
and consider other options.
In our experience, the same dose and schedule should be maintained
throughout the early cycles of therapy, whenever possible, to increase
the likelihood of achieving a response.
3.2. Non-hematologic AEs
With either HMA, patients may occasionally experience an increase
in body temperature during the days of administration. Other key non-
hematologic AEs are described below.
3.2.1. Gastrointestinal AEs
Gastrointestinal AEs are common with HMAs, and may include
nausea, vomiting, diarrhea and constipation. In Phase 3 trials, most of
these were graded mild or moderate, and severe events were relatively
rare (Dombret et al., 2015; Nieto et al., 2016). Pre-medication for the
prevention of nausea and vomiting should be considered (Vidaza
SmPC), and then re-evaluated throughout treatment, taking into ac-
count the patient’s individual symptoms. In general, these events are
easily managed symptomatically using anti-emetics for nausea and
vomiting (before administering the drugs), anti-diarrheals for diarrhea,
and laxatives or stool softeners for constipation. Constipation often
relates to the use of anti-emetics and resolves in the intervals between
cycles.
It is recommended to discuss all of these possible AEs with the pa-
tient before starting treatment so that they can be prevented with ap-
propriate diet or self-medication.
3.2.2. Local AEs
Injection-site reactions are common with subcutaneously adminis-
tered azacitidine, although these events were not associated with any
discontinuations in the AZA-AML-001 study (Dombret et al., 2015).
Injection sites should be rotated, and cases of rash, inflammation,
pruritus or erythema can be managed with antihistamines, corticos-
teroids, evening primrose oil (Platzbecker et al., 2010), or non-steroidal
anti-inflammatory drugs. Some patients have more severe skin reac-
tions, and hemorrhagic reactions can occur, particularly when patients
are severely thrombocytopenic.
There are no reports of local AEs with decitabine, even in cases of
accidental extravasation. Unless venous access is particularly difficult,
the use of a central venous catheter is not required.
4. Use of concomitant medications
Hydroxyurea is frequently used in AML patients to reduce white
blood cell counts. However, when used in combination with decitabine
or azacitidine in cell lines, hydroxyurea antagonized DNA methylation
inhibition (Choi et al., 2006). Hence, it should not be used con-
comitantly with HMA therapy. However, this effect can be avoided
through sequential use (Choi et al., 2006), and hydroxyurea may be
used, if required, before initiating HMA treatment.
No formal clinical drug interaction studies have been conducted
with either decitabine or azacitidine (Dacogen SmPC; Vidaza SmPC).
However, neither appears to be metabolized via cytochrome P450
isoenzymes and interactions relating to these enzymes are considered to
be unlikely.
5. Special populations
No formal studies have been conducted with decitabine or azaciti-
dine in patients with hepatic impairment (Dacogen SmPC; Vidaza
SmPC). Patients should be monitored closely, but no specific mod-
ifications to the dose or frequency of administration are recommended.
In a study of patients with various tumor types who had renal im-
pairment, azacitidine pharmacokinetics were unaffected (Laille et al.,
2014). The SmPCs for both approved HMAs state that these drugs can
be used in patients with renal impairment, and no specific modifica-
tions to the dose or frequency of administration are recommended
(Dacogen SmPC; Vidaza SmPC). However, caution should be exercised
and close monitoring may be necessary, particularly in patients with
severe renal impairment. Indeed, a study of 41 HMA-treated patients
with renal insufficiency (n=17 AML) suggested a higher incidence of
toxicity in these individuals (Batty et al., 2010). No trials have been
performed in dialysis patients, although case studies in higher-risk MDS
have demonstrated successful use of azacitidine (Ham et al., 2012;
Yoshihiro et al., 2016).
A recent retrospective evaluation noted a higher incidence of grade
≥ 3 cardiac and respiratory toxicities in decitabine-treated AML pa-
tients with renal dysfunction (creatinine clearance ≥ 60mL/min)
versus those with normal renal function (creatinine clearance<60mL/
min) (Levine et al., 2017). No prospective evaluations have been per-
formed.
Patients with a history of severe congestive heart failure or clinically
unstable cardiac disease were
excluded from the registration trials of both decitabine and azaci-
tidine (Kantarjian et al., 2012; Dacogen SmPC; Dombret et al., 2015;
Vidaza SmPC). Hence, their safety and efficacy in these patients has not
been established. Azacitidine has been associated with a significant
increase in cardiac events in newly diagnosed AML patients with a
history of cardiovascular or pulmonary disease (Vidaza SmPC) and
caution is advised when using the drug in these individuals. However,
in our experience, both HMAs can be delivered safely to these patients if
carefully monitored, because of the lack of direct myocardial toxicity.
6. Predicting response to HMAs
The ability to predict which patients will respond best to HMA
treatment would be valuable given that clear signs of response are often
not evident for up to 6 cycles (and occasionally longer) (Tawfik et al.,
2014; Thépot et al., 2014; He et al., 2017b). This would allow un-
necessary and potentially toxic treatment to be avoided. Here we
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discuss only AML-related factors although many other variables have
been evaluated in MDS.
Multivariate analyses have shown that several baseline clinical
factors are associated with reduced OS in AML patients treated with
decitabine or azacitidine. In frontline treatment, these include elevated
white blood cell count, adverse cytogenetic category, poorer Eastern
Cooperative Oncology Group performance status, and increasing age
(Mayer et al., 2014; Falantes et al., 2018). In patients with bone marrow
blasts ≥ 30% and a white blood cell count< 15,000/μL in DACO-016,
median OS was significantly longer with decitabine versus TC (8.6 vs
4.7 months, respectively; HR: 0.67; p= 0.0033) (Kadia et al., 2015). In
relapsed/refractory AML, the presence of> 5% circulating blasts
or> 20% bone marrow blasts were significant predictors of decreased
OS in HMA-treated patients (Stahl et al., 2018a). However, none of
these factors is sufficiently predictive of outcomes in AML treated with
an HMA relative to other therapies to be used as a baseline biomarker
for supporting treatment decision making.
Furthermore, none of these factors can be used to predict the time to
response in HMA-treated patients (Boddu et al., 2018a). Hence, al-
though research continues, there is currently no validated clinical
marker for predicting response.
Genetic factors may be more useful in predicting potential re-
sponders to HMAs. For example, a sub-analysis of data from the DACO-
016 study suggested that decitabine may be particularly beneficial in
patients with monosomal karyotype, offering significant improvements
in median OS relative to TC (6.3 vs 2.6 months, respectively; HR: 0.52;
95% CI: 0.29–0.93; p=0.025) in a group that normally has a very poor
prognosis (Wierzbowska et al., 2018).
Potential associations with improved outcomes with HMAs have
also been found in patients with mutations in various genes, including
DNMT3A, IDH1, IDH2, TET2 (Emadi et al., 2015; Tang et al., 2016).
However, their predictive value in guiding HMA treatment remains
unclear.
Encouraging data have been achieved in HMA-treated patients with
an underlying TP53 mutation, which is associated with a particularly
poor prognosis in patients treated with standard induction che-
motherapy (Bowen et al., 2009; Rücker et al., 2012). In a study of 116
patients with AML (78%) or MDS (22%) treated with decitabine, re-
sponse rates were higher among patients with an unfavorable cytoge-
netic risk profile versus intermediate or favorable cytogenetic profile
(67% vs 34%, respectively; p < 0.001), and among patients with TP53
mutations versus those with wild-type TP53 (100% vs 41%; p < 0.001)
(Welch et al., 2016). In addition, OS was not negatively affected by
unfavorable cytogenetics or TP53 mutation. Furthermore, even out-
come after transplant was not influenced by TP53 mutations in patients
receiving decitabine. However, this study was largely based on the
more intensive 10-day decitabine regimen rather than the standard 5-
day schedule, and hence confirmatory data are required in AML pa-
tients treated with the latter. With azacitidine, an exploratory sub-
analysis of data from AZA-AML-001 suggested that median OS might be
longer in patients with TP53-mutated AML treated with azacitidine
compared with conventional care regimens (7.2 vs 2.4 months, re-
spectively; p= 0.069), although the analysis was underpowered to
achieve statistical significance (Tang et al., 2016). Hence, more work is
required to better understand the association between TP53 mutations
and outcomes in HMA-treated patients with AML.
It has also been suggested that the type of AML a patient has may
impact on outcomes with HMAs. A recent analysis found that among
individuals with AML with myelodysplasia-related changes (one of
several types of AML defined by the WHO (Döhner et al., 2017)),
median OS was significantly prolonged with azacitidine relative to
conventional care regimens (8.9 vs 4.9 months, respectively; HR: 0.74;
95% CI: 0.57–0.97) (Seymour et al., 2017). Another population of in-
terest could be those with secondary AML, who typically experience
poor outcomes with intensive therapy compared to patients with de
novo AML (Granfeldt Østgård et al., 2015; Hulegårdh et al., 2015), and
might therefore benefit from alternative treatment strategies. Recent
observational data suggested that the median OS of decitabine-treated,
elderly AML patients is not influenced by the type of AML (de novo
AML, 12.4 months; secondary AML, 16 months; p= 0.8) (Borlenghi
et al., 2017).
However, although these observations are interesting and set the
stage for future investigations, the choice of therapy with HMAs should
not be made solely on the basis of predictive variables that have yet to
be validated in larger cohorts of patients.
7. Assessing response to treatment
Once HMA therapy is initiated, it is important to retain patients on
the treatment for long enough that response can be accurately assessed.
Median times to best response in HMA-treated patients are around 3–5
cycles (Tawfik et al., 2014; Thépot et al., 2014; He et al., 2017b), and a
study of azacitidine in newly diagnosed AML showed that 15% of best
responses were reached only after> 6 cycles (Thépot et al., 2014).
Time to response does not influence OS (Boddu et al., 2018a). Hence,
patients should be maintained on HMA treatment for a minimum of 4–6
cycles (Dacogen SmPC; Vidaza SmPC), as long as they experience no
serious side effects or clear progressive course in their disease.
A recent meta-analysis of 26 trials in newly diagnosed AML (20 of
which involved decitabine or azacitidine) demonstrated a significant
correlation between the achievement of complete remission (CR) or CR
with incomplete blood recovery (CRi) and median OS (Agarwal et al.,
2017). The deepest level of response – measurable residual disease
(MRD) negativity – already has an accepted, independent predictive
value in AML patients receiving intensive treatment (Döhner et al.,
2017); the achievement of MRD negativity has also recently been
shown to reduce the risk of relapse in HMA-treated patients (Boddu
et al., 2018b).
However, depth of response is not necessarily a good indicator of
survival benefit in patients treated with an HMA, and both decitabine
and azacitidine can confer an OS benefit in the absence of CR (Dombret
et al., 2015; He et al., 2015), contradicting the dogma that achievement
of CR as condition of successful therapy in AML. For example, in AZA-
AML-001, azacitidine demonstrated an OS benefit compared with
conventional care regimens even among those patients who failed to
achieve a CR (6.9 vs 4.2 months, respectively; HR: 0.77; 95% CI:
0.62–0.95; p=0.017) (Dombret et al., 2015). Similarly, in DACO-016,
when patients achieving CR were excluded, OS was improved in pa-
tients who achieved transfusion independence, suggesting that reaching
CR is not a prerequisite for treatment benefit (He et al., 2015). Even
long-lasting stable disease (≥ 6 cycles) can confer a significant OS
benefit in newly diagnosed AML patients treated with an HMA
(Williams et al., 2016).
In a study of 302 AML patients treated with azacitidine, OS was
significantly longer in patients who achieved a hematologic improve-
ment compared with those who did not (Pleyer et al., 2014). As noted in
recent ELN recommendations (Döhner et al., 2017), HMAs appear to
alter the natural course of AML in some patients who do not achieve CR.
Hence, hematologic improvement can also yield clinical benefit apart
from survival, including reductions in transfusions and improved
quality of life (Dombret et al., 2015; He et al., 2015; Döhner et al.,
2017).
HMA treatment should therefore be continued for as long as the
patient continues to benefit, in the absence of overt disease progression
(Dacogen SmPC; Vidaza SmPC). Premature discontinuation of HMA
treatment must be avoided. Patients who discontinue therapy after
achieving partial or complete remission but before treatment failure
may lose their response rapidly after discontinuation (Cabrero et al.,
2015). The prognosis following HMA failure is typically poor, with a
median OS of less than 6 months (Jabbour et al., 2014).
Given all of the above, if CR is not a good surrogate for survival with
HMAs, this raises the question of whether there are any other potential
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markers of likely improved survival that can be assessed early during
treatment with these drugs. To date, there are none. Several factors
have been linked with positive outcomes with HMAs, including platelet
response during early cycles of treatment (van der Helm et al., 2011;
Jung et al., 2015; Park et al., 2017), early fetal hemoglobin induction
(Stomper et al., 2018) decreased need for transfusions (He et al., 2015;
Minden et al., 2015), and low numbers of dose modifications (Minden
et al., 2015). However, none has been prospectively associated in im-
proved survival. Hence, we do not recommend using any of these to
determine whether or not to continue with HMA treatment.
8. Use of HMAs in other settings
8.1. Younger age
HMAs are most often used in older individuals who are unsuitable
for intensive chemotherapy. Indeed, the registration trials of decitabine
and azacitidine in AML were conducted in patients aged ≥ 65 years
(Kantarjian et al., 2012; Dombret et al., 2015). However, in many
countries, the indications for both drugs contain no age restrictions
(Dacogen SmPC; Vidaza SmPC), and ELN recommendations do not
make any age-based differentiation (Döhner et al., 2017). Hence, HMAs
should also be considered in younger patients who are not candidates
for intensive chemotherapy, for example those with severe comorbid-
ities.
8.2. HMAs pre-hematopoietic stem cell transplant
Independent of age, treatment outcomes in patients with TP53
mutations, complex karyotype or monosomal karyotype are particularly
dismal (Döhner et al., 2017). In these patients, HMAs could be bene-
ficial as a bridge to transplant. The use of HMAs to convert patients
from MRD positivity to MRD negativity ahead of transplant is also
currently under investigation.
It has been suggested that HMAs could be used as a bridge to
transplant in some patients who are not suitable for standard induction
chemotherapy. This suggestion is based on the hypothesis that the
lower toxicity of these agent reduces upfront mortality and could also
enhance the graft-versus-leukemia effect by upregulating human leu-
kocyte antigen expression (Lübbert et al., 2009; Malik and Cashen,
2014). Small studies have demonstrated the feasibility of this approach:
a number of patients with newly diagnosed or relapsed/refractory
disease who achieved a CR with an HMA successfully proceeded to
transplant, despite having been unsuitable for standard induction che-
motherapy (Lübbert et al., 2009; Grunwald et al., 2017; Stahl et al.,
2018b). Based on these observations, the term of ‘inDACtion’ has been
coined (Michael Lübbert, personal communication, 2009). A Phase 3
study is currently ongoing comparing 10-day decitabine versus stan-
dard 7+3 induction chemotherapy ahead of allogeneic transplantation
(NCT02172872). However, by definition, this trial is being conducted
in a cohort of patients that is eligible for intensive chemotherapy. Data
from larger studies using HMAs as a bridge to transplant in patients
who are not suitable for intensive induction chemotherapy are still
awaited.
8.3. Maintenance therapy with HMAs
Maintenance therapy has typically not been considered as a stan-
dard element of AML treatment, owing to a lack of evidence of benefit
(Döhner et al., 2017). However, there may be a rationale for using
HMAs in the maintenance setting, given that they have hypomethy-
lating activity that is distinct from chemotherapy (Blum et al., 2017).
Early studies have shown promising results using an HMA as a pre-
ventive approach for reducing the risk of relapse post-transplant (de
Lima et al., 2010; Goodyear et al., 2012; Pusic et al., 2015). On the
flipside, a single-arm study of decitabine as maintenance therapy in 134
younger AML patients (< 60 years) who did not receive allogeneic
transplantation in first CR achieved disease-free survival (DFS) rates
that were similar to comparable historical controls, suggesting no ad-
ditional benefit (Blum et al., 2017). However, in a randomized trial of
117 older patients (≥ 60 years) with AML or MDS in CR/CRi after ≥ 2
cycles of intensive chemotherapy, azacitidine maintenance significantly
improved DFS relative to observation (12-month DFS: 63% vs 39%,
respectively; p < 0.005) (Huls et al., 2017). OS was improved with
azacitidine after censoring patients who received an allogeneic trans-
plantation (12-month OS: 83% vs 64%, respectively; p= 0.04) (Huls
et al., 2017). An oral formulation of azacitidine is also being studied in
the maintenance setting in a Phase 3 randomized, controlled trial
(Roboz et al., 2016); eligible patients are aged ≥ 55 years in first CR,
and results are expected in 2019.
8.4. Relapsed/refractory AML
In relapsed/refractory AML, ELN recommendations currently ac-
knowledge that no specific regimen has emerged as the standard of care
(Döhner et al., 2017). The efficacy of HMAs has been modest in patients
relapsing post-transplant (CR rates of 15–27% and 2-year survival of
12–29%) (Schroeder et al., 2015; Craddock et al., 2016) or with re-
lapsed/refractory disease after intensive chemotherapy (CR rates of
16–21% and median OS of 6–9 months) (Ivanoff et al., 2013; Ritchie
et al., 2013; Itzykson et al., 2015; Stahl et al., 2016, 2018a). However,
given the paucity of options in these patients, HMAs remain a reason-
able choice, particularly in those with no clinical trial alternative.
The use of HMAs, particularly decitabine, to sensitize leukemia cells
to further chemotherapy (an approach known as ‘epigenetic priming’)
has also been assessed in small studies in the relapsed/refractory AML
setting. Rates of CR/CRi of up to 48% have been achieved, suggesting
that this approach may be worthy of further investigation in larger
trials (Jain et al., 2016; Halpern et al., 2017).
9. Conclusions
HMAs are a valuable upfront treatment option in AML patients who
are not considered to be suitable for intensive chemotherapy, irre-
spective of age. Treatment should be continued for a minimum of 4–6
cycles to ensure that patients have an adequate opportunity to respond
(Dacogen SmPC; Vidaza SmPC). Delivery of insufficient numbers of
cycles is a key reason for HMA failure, and premature discontinuation
must be avoided. Both of the approved HMAs can confer an OS benefit
in the absence of CR (Dombret et al., 2015; He et al., 2015), and hence
treatment should continue for as long as the patient achieves benefit, in
the absence of overt disease progression (Dacogen SmPC; Vidaza
SmPC). Awareness and careful management of AEs may help to ensure
sufficient duration of therapy.
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